For information on this past event please contact Meetings Management

Provisional Conference Program

Wednesday 10th May 2006

08.50-09.00
Welcome & Opening Remarks
Professor Mark Glassy (HAH 2006 Conference Chairman)

09.00-10.00
OPENING KEYNOTE LECTURE
‘Antibodies: Key Determinants of Normal and Malignant B Cells’
Klaus Rajewsky (CBR Institute for Biomedical Research, Boston, USA)

SESSION 1:
CANCER I
Moderators: Mark C. Glassy (Shantha West, San Diego, USA) and Frank Hensel (Acceptsys Inc., Germany)

10.00-10.30
‘Feasibility of human antibody cocktails in oncology’
Mark C. Glassy (Shantha West, San Diego, USA)

10.30-10.50
‘Antibody therapeutic approaches in cancer’
Paul Parren (Genmab, Utrecht, The Netherlands)

10.50-11.10
‘Proteomic mapping & immunotargeting of endothelial caveolae for transcytosis and penetration into solid tumours and lungs’
Jan Schnitzer (Sidney Kimmel Cancer Center, San Diego, USA)

11.10-11.30
Coffee Break

SESSION 2:
CANCER II
Moderators: Zdenka L. Jonak (GSK, USA) and Frank Hensel (Acceptsys Inc., Germany)

11.30-12.00
‘Antibody microarrays for cancer proteome analysis’
Carl Borrebaeck (Lund University, Sweden)

12.00-12.20
‘Anti-tumor effects of human monoclonal antibody HMMC-1 on lymph node metastasis of endometrial cancer’
A. Suzuki et al. (Keio University, Tokyo, Japan)

12.20-12.40
‘Anti-vascular endothelial growth factor receptor 1 antibody as an antagonist for cancer therapy through targeting cancer cells and tumour angiogenesis’
Yan Wu et al. (ImClone Systems Incorporated, New York, USA)

12.40-13.00
‘Recruitment of NK cells to kill tumor cells’
Melvin Little (Affimed Therapeutics, Heidelberg, Germany)

13.00-15.00
Lunch & Leisure Time for Delegates

SESSION 3:
CANCER III
Moderators: Mark C. Glassy (Shantha West, San Diego, USA) and Carl Borrebaeck (Lund University, Sweden)

15.00-15.30
‘Pathway of antibody SAM-6 induced lipo-apoptosis’
F. Hensel, S. Brandlein, A. Dreykluft, N. Rauschert, L. Rasche, K. Muller, E. Wozniak and H.P. Vollmers (University of Wurzburg, Wurzburg, Germany)

15.30-16.00
‘N-glycosylation in the immunoglobulin variable region is a potential survival strategy for human follicular lymphoma cells’
Kathy Potter (University of Southampton, UK)

16.00-16.20
‘Characteristics of tumor gangliosides revealed by B cells infiltrating human breast carcinomas’
B. Kotlan, J. Toth, M. McKnight and M.C. Glassy (National Medical Center, Budapest, Hungary)

16.20-16.40
‘Generation and application of a panel of phospho-specific antibodies against 13 in vivo phosphorylation sites of the tumor suppressor RB protein’
Yoichi Taya et al. (National Cancer Research Institute, Tokyo, Japan)

16.40-17.00
‘Targeting axon guidance molecules in tumor biology’
Yan Wu (Genentech Inc., South San Francisco, California, USA)

17.00-17.15
‘Cytotoxic activity of human anti-thyroperoxidase auto-antibodies: an alternative therapeutic approach in thyroid cancers’
Sandra A. Rebuffat et al. (CNRS, Montpellier, France)

17.15-17.30
‘Antibody-based reagents against human ovary cancer: their contribution to targeted therapy’
Mariangela Figini et al. (Istituto Nazionale Tumori, Milan, Italy)

17.30-17.45
‘In vitro anti-tumoral activity of baculovirus-expressed chimeric recombinant anti-CD4 antibody 13B8.2 on T cell lymphomas’
Samuel Troadec et al. (CNRS, Montpellier, France)

17.45-18.00
‘Targeting the HER2 antigen for the treatment of disseminated peritoneal disease: Radioimmunotherapy (RIT) with Lutetium-177 labeled Herceptin’
Lanea Marie Marcelle Keller et al. (NIH, Bethesda, Maryland, USA)

18.00-18.30
‘Cancer immunotherapy’
Zdenka L. Jonak (GlaxoSmithKline, King-of-Prussia, Pennsylvania, USA)

19.00-20.00
HAH 2006 Welcome Reception